Guinea-Bissau Halts Controversial US-Funded Hepatitis B Vaccine Trial on Newborns

The final authorization for clinical research involving human subjects rests with the host nation's health ministry, a safeguard designed to protect vulnerable populations. In Guinea-Bissau, that regulatory firewall has halted a controversial United States-funded study that planned to withhold the hepatitis B birth vaccine from thousands of newborns.[1]

Health Minister Quinhin Nantote announced on Tuesday that the transitional government never approved the trial, contradicting reports that local authorities had given researchers the green light. The proposed study, led by Danish researchers from the Bandim Health Project, intended to enroll 14,000 infants in the West African nation.[1][2]

Half of the newborns would receive the standard hepatitis B vaccine at birth, while the other half would be denied the dose for their first six weeks of life. Nantote stated that the ministry did not authorize the tests under the terms presented, emphasizing strict compliance with international ethical principles.[2][3]

The denial effectively blocks a $1.6 million project funded by the U.S. Centers for Disease Control and Prevention that has drawn intense international criticism. Public health experts and the World Health Organization have condemned the trial's design, arguing that withholding a proven vaccine violates fundamental medical ethics.[1]

"Any scientific research initiative involving human beings, particularly children, must strictly comply with applicable national legislation, international ethical principles, competent evaluation and approval mechanisms," Nantote told reporters in Bissau. He added that the government takes its responsibility to protect citizens seriously and will not bypass established reviews.[1][5]

The Dispute Over Approval

The controversy reignited last week when an ethics committee at the University of Southern Denmark approved the trial's revised protocol. Members of the Danish committee were reportedly informed that officials in Guinea-Bissau had already authorized the updated design, a claim that influenced their votes to proceed.[5][6]

The Guinean health ministry's public denial directly contradicts that narrative, exposing a severe breakdown in communication between the European researchers and the host country. The Bandim Health Project, directed by researchers Peter Aaby and Christine Stabell Benn, has operated in Guinea-Bissau for decades.[2][6]

The research group focuses on the non-specific effects of vaccines, theorizing that certain immunizations might influence overall mortality in ways unrelated to their target diseases. To test this hypothesis, the researchers designed a randomized controlled trial that required a control group of unvaccinated infants.

Researchers defended the protocol by pointing out that Guinea-Bissau's current national schedule does not routinely administer the hepatitis B vaccine until an infant is six weeks old. The Bandim team argued that no child in the study would receive fewer vaccines than the current national policy dictates.

However, the government has already committed to introducing a universal birth dose by 2028, rendering the trial's premise highly contentious. The WHO strongly opposed the study, noting that the hepatitis B birth dose is an essential public health intervention used in over 115 countries.

High Stakes for Newborn Health

Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. Transmission from mother to child during birth is the most common route to lifelong infection, making immediate intervention the standard of care globally.[2]

According to the WHO, approximately 90 percent of newborns infected during childbirth become chronic carriers. This early exposure places them at a significantly higher risk of developing cirrhosis and liver cancer later in life compared to those infected as adults.[1]

The disease burden in Guinea-Bissau is exceptionally high, making the timing of vaccination critical. Estimates suggest that more than 12 percent of adults in the country live with chronic hepatitis B, and the infection rate among children under five sits at roughly 2 percent.[2][4]

That pediatric infection rate is twenty times higher than the global target of 0.1 percent, underscoring the urgent need for early intervention. Administering the vaccine within 24 hours of birth is the most effective method to prevent perinatal transmission.[4][5]

Medical professionals argue that conducting a randomized trial that intentionally delays this dose exposes the control group to unnecessary and severe risks. Critics have labeled the experimental design as exploitative, particularly when conducted in a resource-constrained setting where alternative treatments are scarce.[2][3]

"It's completely unethical that this trial is even proposed," said BK Titanji, a researcher at Emory University, noting that a safe vaccine has been available for decades. She added that conducting such a study on vulnerable newborns requires the highest level of ethical scrutiny.[1]

Political and Financial Backing

The trial's funding and political support have added layers of complexity to the ethical debate. The U.S. CDC awarded the $1.6 million grant without competition, a move that placed American public health dollars at the center of a global controversy.[2]

The project has also been championed by Robert F. Kennedy Jr., the current secretary of the U.S. Department of Health and Human Services. Kennedy has publicly praised the Danish researchers, referring to them as the "deities of vaccine research" at a recent conference.

Kennedy has frequently cited their previous work to support his claims regarding the unintended consequences of childhood immunizations. This high-level endorsement has fueled concerns among mainstream scientists that the trial is intended to generate data supporting anti-vaccine policies rather than advancing global health.[1]

The Africa CDC intervened earlier this year, engaging with Guinea-Bissau's health ministry to highlight the ethical challenges inherent in the trial's design. Dr. Jean Kaseya, the director general of the Africa CDC, confirmed that local officials had requested support for a thorough technical review.[2]

Following the international outcry, the U.S. Department of Health and Human Services issued a statement clarifying its position. The department confirmed that the study has not been approved and remains on hold, aligning with the Guinean government's stance despite the Danish committee's recent vote.[1][2]

The Path Forward for Guinea-Bissau

With the trial officially blocked by the health ministry, Guinea-Bissau is focusing on its broader public health objectives. The transitional government remains committed to its plan to roll out the universal hepatitis B birth dose to all newborns by 2028.

Structural barriers, including cold-chain logistics and healthcare worker training, currently delay the implementation, rather than any scientific uncertainty about the vaccine. The WHO has offered comprehensive support to help the country accelerate this rollout and overcome these logistical hurdles.

The organization stands ready to assist with antenatal screening, last-mile logistics, and strategies for delivering the vaccine within 24 hours of birth. This collaborative approach aims to strengthen the national healthcare system without subjecting infants to experimental delays.

The rejection of the Bandim Health Project trial marks a significant moment for medical sovereignty in West Africa. By enforcing its regulatory authority, Guinea-Bissau has signaled that international research initiatives must prioritize the immediate well-being of local populations over theoretical scientific inquiries.[1]

The immediate focus now shifts to the University of Southern Denmark and the CDC, who must decide whether to formally cancel the grant or attempt to redesign the study. The health ministry's ruling ensures that when the birth dose is finally introduced, it will be distributed universally.[2]